PD-L1 by clone 22C3 [Presence] in Tissue by Immune stain

PD-L1 by 22C3 Tiss Ql ImStn

Definition

This term should be used to report the presence of PD-L1 (CD274) protein expression in tumor cells as determined by immune staining with anti-PD-L1 clone 22C3. Patients with certain cancers, such as non-small cell lung cancer (NSCLC), whose tumors are positive for PD-L1 by 22C3 are eligible for anti-programmed death 1 (PD-1) receptor antibody therapy with pembrolizumab, which effectively prevents the binding of PD-L1 to PD-1. The percentage of viable tumor cells that show partial or complete PD-L1 membrane staining is reported using [LOINC: 83053-9]. A tumor with <50% staining by 22C3 is considered PD-L1 negative, and >= 50% is considered PD-L1 positive. This term was created for, but is not limited in use to, the Dako PD-L1 22C3 pharmDx test kit, which, as of November 2016, is FDA-approved as a companion diagnostic to assess whether patients with specific cancers are eligible for pembrolizumab therapy.

B7 homolog 1; B7-H1; CD274; Cluster of differentiation 274; i; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; PATHOLOGY; PDL1; PD-L1; PD-L1 by 22C3; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified